<DOC>
	<DOCNO>NCT00738582</DOCNO>
	<brief_summary>This research do find pemetrexed cisplatin work well give together experimental drug call MORAb-009 patient malignant pleural mesothelioma .</brief_summary>
	<brief_title>An Efficacy Study MORAb-009 ( Amatuximab ) Subjects With Pleural Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Primary Confirmed diagnosis malignant pleural mesothelioma ( MPM ) follow characteristic : unresectable disease ( otherwise candidate curative surgery ) ; epithelial type biphasic ( mixed ) type low sarcomatous content . Measurable disease Screening compute tomography ( CT ) ( magnetic resonance image [ MRI ] ) . KPS great equal 70 % Screening . Life expectancy least 3 month Primary Sarcomatous type mesothelioma Prior systemic therapy radiotherapy MPM ; local radiotherapy symptom control ( ie , noncurative intent ) permit . Confirmed presence CNS tumor involvement . Evidence active malignancy require treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>